MAGEA3 and cancer: Nevertheless, as promising approach cancer vaccines such as TAAs expressing viruses or TAAs coated viral particles continue to enter clinical trials such as MAGE-A3 expressing viruses (NCT02285816), papillomavirus E6E7 antigen expressing viruses (NCT03618953) as well as innovative peptide-coated conditionally replicating adeno-virus - PeptiCRAd-1 (NCT05492682) [9].